Bioprocessing White Papers

1. The Strategic Value Of In-House Delumping For Homogeneous API Production 9/9/2026

   API batch homogeneity supports efficient manufacturing. Controlled delumping improves powder flow and chargeability while maintaining particle size integrity and reducing GMP-scale risks.

2. Enhancing Quality And Environmental Monitoring Efficiency Through Paperless Sampling 9/9/2026

   At roughly 600,000 samples per year, manual EM documentation creates real compliance and operational risk. This whitepaper details how a fully integrated digital sampling system addresses both.

3. Controlling Complexity In ADC Formulation Development 9/9/2026

   ADC formulation development requires a molecule-specific approach that accounts for the interplay between antibody, linker, and payload, and the stability trade-offs that mAb development experience cannot fully anticipate.

4. An Integrated Analytical Approach To Lipase Risk Management In Biologics Development 9/8/2026

   Conventional HCP testing cannot confirm whether residual lipases remain enzymatically active. Here, the authors examine why functional activity data are essential for managing polysorbate-related stability risk in biologics development.

5. Why The Traditional Approach To Evaluating Gene Editing Is Not Your Only Option 9/7/2026

   De-risk genetic medicine development with a phased evaluation approach. Gain rapid, data-driven feasibility insights before major investments, enabling smarter decisions and faster clinical progress.

6. Digital CMC Maturity: Rethinking QTTP And Control Strategy 9/2/2026

   Digital CMC maturity depends on structured, science- and risk-based knowledge. Learn how connecting development, validation, regulatory, and lifecycle information can accelerate timelines.

7. Enhancing mAb Production: Advanced Downstream Purification Strategies 9/1/2026

   Explore how process optimization can address downstream mAb manufacturing bottlenecks, reduce labor and consumable costs, and support more efficient production without compromising performance.

8. Optimizing mAb Production: Upstream Process Intensification Strategies 9/1/2026

   See how integrated upstream and downstream intensification strategies can increase monoclonal antibody yield, streamline workflows, improve facility utilization, and reduce manufacturing costs.

9. Determining The True Cost Of Single-Use Fluid Management 8/24/2026

   Looking beyond unit price reveals how reliability, leak prevention, and shelf life affect bioprocessing costs. Make purchasing decisions that support resilient and predictable operations.

10. Improving AAV Manufacturing: Advancements In Full Capsid Enrichment 8/19/2026

    As AAV manufacturing matures, integrated optimization of capture, buffer chemistry, load conditioning, and AEX polishing enables scalable full capsid enrichment, improving product quality and manufacturability.